ReviewClinical and experimental nephrology2026
Gallstones and acute cholecystitis in CKD and dialysis: an underrecognized biliary burden in nephrology.
Review in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallstones and acute cholecystitis are not usually regarded as core nephrology problems, yet accumulating observational evidence suggests that their burden is increased in chronic kidney disease (CKD), particularly in advanced predialysis CKD and end-stage kidney disease (ESKD). Plausible contributors include impaired gallbladder motility related to uremia-associated autonomic dysfunction, shared metabolic risk clustering, and, in selected patients, hemodynamic vulnerability related to intradialytic hypotension or low-output states. The central clinical issue may be underrecognition. In CKD and dialysis, abdominal complaints are often nonspecific and may overlap with uremic or intercurrent illness-related symptoms. In addition, uncomplicated acute cholecystitis may present early with absent or only mild hepatobiliary enzyme abnormalities, whereas marked bilirubin elevation or a cholestatic pattern should prompt evaluation for choledocholithiasis or cholangitis. Ceftriaxone-associated pseudolithiasis and glucagon-like peptide-1 receptor agonist exposure may further complicate the diagnostic picture. Although evidence linking CKD itself to primary acute cholangitis is less robust than that linking CKD to gallstones and acute cholecystitis, biliary obstruction and endoscopic intervention remain relevant because advanced CKD and ESKD may increase procedure-related morbidity. Emerging data also caution against reflexive therapeutic nihilism: source control should not be deferred solely because a patient has advanced CKD or dialysis dependence, and gallbladder drainage may serve as a planned bridge or alternative in selected high-risk patients. This focused review summarizes the epidemiologic links, plausible mechanisms, diagnostic pitfalls, and practical management implications of gallstones and acute cholecystitis in CKD and dialysis, and highlights why biliary disease should be recognized as an underappreciated comorbidity in nephrology care.
Indexed as
Identifiers
42573957What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.